New research reveals that stopping GLP-1 medications like Ozempic might not be as permanent as we think — and that's actually encouraging news for millions of people managing type 2 diabetes. So here's something that might surprise you: if you've started a GLP-1 medication like Ozempic, Wegovy, or Mounjaro and found yourself falling off the wagon, you're definitely not alone. And according to fresh research presented at the Endocrine Society's annual meeting, the pattern might be more "pause and resume" than "give up entirely." Let's dig into what scientists discovered when they looked at insurance records from over 60,000 Americans with type 2 diabetes. Spoiler alert: the numbers are pretty eye-opening. ## The Start-Stop Reality Here's the deal: about 4 out of every 10 patients stopped their GLP-1 medication within the first year of starting. By year two? Nearly 6 in 10 had called it quits. That's a lot of people discontinuing treatment. But here's where it gets interesting. When researchers dug deeper, they found that more than half of those who stopped actually restarted therapy within a year, and almost two-thirds went back on their medication within two years. "We think this suggests that for many patients, these medications aren't being abandoned permanently," explained Sainikhil Sontha, a researcher at Boston University School of Public Health. "Use is more start-and-stop than most people assumed." I don't know about you, but I find that strangely comforting. It means that when life gets in the way — whether it's side effects, cost concerns, or just the chaos of everyday life — people aren't necessarily throwing in the towel for good. ## Why Do People Stop? The study pinpointed several factors that made people more likely to discontinue their medication: First up: side effects. About 37% of patients who experienced nausea or other gastrointestinal issues stopped treatment within the first year. That's significant. These medications can be genuinely tough on the digestive system, especially when you're first starting out. There's also a socioeconomic angle. People covered by Medicaid or Medicare were more likely to stop than those with other insurance types. And Black patients had higher discontinuation rates compared to other groups — a disparity that points to deeper systemic issues in healthcare access and support. ## The Doctor Factor Here's something worth noting: patients whose first GLP-1 prescription came from an endocrinologist were 10% less likely to stop treatment. Ten percent might not sound huge, but in large populations, that's a lot of people staying on medications that genuinely help them. This suggests that specialist care might come with better guidance on managing side effects, more realistic expectations about the adjustment period, and perhaps more tailored follow-up support. If you're struggling on a GLP-1 medication, having a specialist in your corner could make a real difference. ## Newer Isn't Always Just Marketing The research also revealed that newer GLP-1 drugs had noticeably better "persistence" rates — meaning people stayed on them longer. Patients taking tirzepatide (sold as Mounjaro) were 41% less likely to discontinue compared to those on older medications like liraglutide. Semaglutide users showed a 28% improvement over the older drugs. Now, I'm not saying pharmaceutical companies always have your best interests at heart. But there does seem to be something genuinely different about these newer formulations — whether it's fewer side effects, more convenient dosing, or just better overall tolerability. ## Why This Matters More Than You Think Here's the thing about GLP-1 medications that often gets lost in the noise: they do more than just manage blood sugar. Consistent use has been shown to protect against heart attacks, kidney disease progression, and other serious complications of type 2 diabetes. "Stopping early may mean missed opportunities to prevent heart attacks, kidney disease progression and other complications," Sontha noted. That's not fear-mongering — that's what the science shows. So while the start-and-stop pattern might be normal, it's worth taking seriously. If you're on one of these medications and struggling to stay consistent, that's a conversation worth having with your doctor. ## What This Means For You If you're currently on a GLP-1 medication and finding it hard to stay consistent, take heart. The research suggests that many people face the same challenges — and many of them find their way back. Some practical thoughts: - Don't suffer in silence. If side effects are driving you away from the medication, there are often ways to manage them. A conversation with your doctor about adjusting doses or switching medications could help. - Seek specialist support. If you're not already seeing an endocrinologist, it might be worth asking for a referral. - Know that restarting isn't failure. If you've already stopped, the fact that nearly two-thirds of people get back on track within two years should feel encouraging, not shameful. The bottom line? These medications are powerful tools for managing type 2 diabetes, but they're not one-size-fits-all. The start-and-stop pattern the research uncovered isn't a sign that these drugs don't work — it's a sign that managing a chronic condition is genuinely hard, and we need better systems in place to support people through the difficult parts. What do you think? Has this research changed how you think about medication adherence? I'd love to hear your perspective. Source: ScienceDaily — https://www.sciencedaily.com/releases/2026/06/260615033838.htm ---

The Surprising Truth About Who Stops (and Restarts) Ozempic and Similar Drugs